Influenza Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Test Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Influenza Diagnostics Market size was more than USD 1.9 billion in 2026 and is set to grow at a 5.51% CAGR between 2027 and 2036, crossing USD 3.25 billion by 2036. The industry revenue for 2027 is calculated at USD 1.99 billion.

• Base Year Value (2026): USD 1.9 billion
• CAGR (2027-2036): 5.51%
• Forecast Year Value (2036): USD 3.25 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Influenza Diagnostics Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 34.66% market share in 2026, supported by advanced testing infrastructure, established laboratory networks, and routine use of rapid and molecular diagnostic technologies.
  • Asia Pacific is projected to expand at a 6.67% CAGR as diagnostic capacity grows, testing adoption increases, and healthcare providers strengthen outbreak monitoring and patient triage practices.

• Segment Momentum:

  • RIDT held a 32.73% market share in 2026 and remains the fastest-growing test type because it enables rapid clinical decision-making, immediate patient management, and efficient high-volume testing during influenza seasons.
  • POCT is expanding fastest as healthcare increasingly requires rapid testing in decentralized settings, allowing quicker triage and reducing delays compared with traditional centralized diagnostic workflows.

• Market Expansion Drivers:

  • Rising influenza burden and seasonal outbreaks increasing demand for rapid diagnostic testing solutions.
  • Growing elderly and pediatric vulnerable populations driving early detection and testing adoption.
  • Expanding government surveillance programs and global flu monitoring initiatives strengthening diagnostic uptake.

• Leading Market Participants:

  Top companies in the influenza diagnostics market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Becton, Dickinson and Company (United States), Hologic, Inc. (United States), QuidelOrtho Corporation (United States), DiaSorin S.p.A. (Italy), Sekisui Diagnostics, LLC (United States), Meridian Bioscience, Inc. (United States), bioMérieux SA (France).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 1.9 billion
  • 2027 Estimated Market Size: USD 1.99 billion.
  • Projected Market Size: USD 3.25 billion by 2036
  • Growth Forecasts: 5.51% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: RIDT (Test Type) | Hospitals (End Use)
  • Emerging Opportunity Segment: RIDT (Test Type) | POCT (End Use)

Market Growth Drivers and Industry Trends

Rising influenza burden and seasonal outbreaks increasing demand for rapid diagnostic testing solutions

The influenza diagnostics market growth is being supported by the recurring burden of influenza infections and seasonal outbreaks that increase the need for timely disease identification. Healthcare providers rely on rapid diagnostic testing to distinguish influenza infections from other respiratory illnesses and support appropriate treatment and infection-control decisions. During periods of elevated transmission, laboratories, hospitals, clinics, and other healthcare settings require diagnostic solutions that can deliver results quickly while handling increased testing volumes. Greater awareness of influenza symptoms and the importance of early diagnosis is also encouraging patients and healthcare professionals to seek testing, particularly when respiratory disease activity rises.

Growing elderly and pediatric vulnerable populations driving early detection and testing adoption

A growing focus on protecting elderly individuals and children, who can be more vulnerable to complications from influenza, is strengthening influenza diagnostics market demand. Early identification allows healthcare professionals to assess infection more promptly and determine appropriate clinical management, particularly for patients with increased risks associated with respiratory illness. Pediatric and elderly care settings therefore require accessible diagnostic solutions that can support rapid decision-making without creating unnecessary delays in treatment. The need for reliable testing is further reinforced by healthcare systems seeking to distinguish influenza from other respiratory infections that may present with similar symptoms.

Expanding government surveillance programs and global flu monitoring initiatives strengthening diagnostic uptake

Government-led surveillance and coordinated influenza monitoring programs are increasing the role of diagnostic testing in tracking disease activity, supporting influenza diagnostics market expansion. Public health authorities depend on laboratory and point-of-care testing data to identify circulating influenza activity, monitor seasonal patterns, detect unusual transmission trends, and guide preparedness measures. Wider surveillance coverage requires healthcare facilities and laboratories to maintain diagnostic capabilities across different settings, including areas where disease monitoring infrastructure is being strengthened. Diagnostic information also supports public health decision-making by improving visibility into influenza circulation and helping authorities respond to changes in respiratory disease activity.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising influenza burden and seasonal outbreaks increasing demand for rapid diagnostic testing solutions	2.00%	High	North America, Europe	High	Near Term
Growing elderly and pediatric vulnerable populations driving early detection and testing adoption	1.80%	High	North America, Asia Pacific	High	Near Term
Expanding government surveillance programs and global flu monitoring initiatives strengthening diagnostic uptake	1.50%	High	North America, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest share of the influenza diagnostics market in 2026, accounting for 34.66% share, supported by advanced healthcare infrastructure, established laboratory networks, and strong emphasis on rapid infectious disease detection. Healthcare providers rely on timely diagnostic testing to guide treatment decisions, manage seasonal outbreaks, and support infection-control practices. Continued adoption of molecular and rapid diagnostic technologies is improving testing efficiency across hospitals, clinics, and diagnostic facilities. Strong public health preparedness and established testing capabilities further sustain regional demand for influenza diagnostic solutions.

Asia Pacific is the fastest-growing region, driven by expanding healthcare access, increasing awareness of infectious disease detection, and strengthening diagnostic infrastructure. Growing investment in hospitals and laboratories is improving the availability of testing technologies across both urban and developing healthcare markets. Greater emphasis on early diagnosis and outbreak preparedness is also encouraging healthcare systems to expand their diagnostic capabilities. As demand for rapid and accessible infectious disease testing increases, influenza diagnostics are gaining broader application across the region.

Key Country Insights

United States

Rapid respiratory testing adoption

In the U.S., influenza diagnostics are driven by widespread adoption of rapid respiratory testing across hospitals, urgent care centers, and retail clinics. Healthcare providers prioritize quick turnaround diagnostics to differentiate influenza from other respiratory infections, supporting clinical decision-making during seasonal surges and integrated point-of-care testing adoption.

Japan

Aging population surveillance focus

In Japan, influenza diagnostics are closely linked to surveillance needs driven by an aging population highly susceptible to respiratory infections. Healthcare facilities emphasize early detection and routine testing in clinical settings, supporting public health monitoring and timely intervention during recurring seasonal outbreaks.

South Korea

Digital health testing integration

In South Korea, influenza diagnostics increasingly integrate with digital health systems that streamline test ordering, reporting, and outbreak tracking. Hospitals and clinics emphasize fast molecular and rapid antigen testing, supported by strong health IT infrastructure that enhances responsiveness during seasonal influenza activity.

Germany

Lab-based diagnostic standardization

In Germany, influenza diagnostics rely strongly on standardized laboratory-based testing protocols within structured healthcare networks. Hospitals and diagnostic labs emphasize high-accuracy molecular assays, with centralized systems supporting consistent reporting and surveillance integration across regional healthcare providers during seasonal influenza cycles.

France

Public health screening reliance

In France, influenza diagnostics are strongly shaped by public health screening frameworks that support national surveillance and outbreak management. Healthcare providers focus on coordinated testing across hospitals and primary care, ensuring early identification of cases and alignment with seasonal vaccination and prevention programs.

Italy

Seasonal outbreak detection systems

In Italy, influenza diagnostics are primarily oriented toward managing recurring seasonal outbreaks through structured detection and reporting systems. Healthcare providers emphasize timely testing in hospitals and community clinics, supporting regional monitoring efforts and enabling responsive clinical management during peak influenza transmission periods.

Segment Leadership and Growth Trends

 

Test Type Segment Analysis: RIDT (Largest & Fastest-Growing Segment)

Rapid influenza diagnostic tests (RIDTs) represented both the largest and fastest-growing test type in the influenza diagnostics market, accounting for a 32.73% share in 2026. Their strong position is supported by the need for rapid and accessible influenza screening, particularly where timely clinical decisions are important. RIDTs provide a practical diagnostic option in settings that require quick assessment without relying on more complex laboratory workflows. Growing emphasis on early identification of influenza infections, efficient patient management, and accessible diagnostic testing continues to support demand for rapid testing solutions across healthcare environments.

End Use Segment Analysis: Hospitals (Largest Segment) vs POCT (Fastest-Growing Segment)

Hospitals remained the largest end-use segment of the influenza diagnostics market in 2026, reflecting the substantial volume of patients requiring diagnostic evaluation and the need for timely identification of respiratory infections in clinical environments. Hospitals rely on influenza testing to support appropriate patient management, infection-control decisions, and differentiation of influenza from other respiratory illnesses. The importance of rapid diagnosis during periods of elevated respiratory disease activity further strengthens demand for reliable testing capabilities. Increasing pressure to improve clinical workflow efficiency and support appropriate treatment decisions is sustaining hospital adoption of influenza diagnostics.

Point-of-care testing (POCT) is expanding rapidly as healthcare providers seek diagnostic capabilities closer to patients and outside centralized laboratory environments. POCT enables faster access to influenza results, supporting timely clinical decisions in settings where immediate diagnostic information can improve workflow efficiency. Its growing relevance across outpatient care, urgent care, and other decentralized healthcare environments is supported by the broader shift toward accessible and rapid diagnostics. Increasing demand for convenient testing and reduced dependence on centralized laboratory processing is strengthening adoption of point-of-care influenza testing.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Test Type	RIDT, RT-PCR, Cell Culture, Others	RIDT	RIDT
End Use	Hospitals, POCT, Laboratories	Hospitals	POCT

Competitive Landscape and Market Positioning

Leading companies in the influenza diagnostics market:

1. Abbott Laboratories (United States)

2. F. Hoffmann-La Roche Ltd. (Switzerland)

3. Thermo Fisher Scientific Inc. (United States)

4. Becton Dickinson and Company (United States)

5. Hologic Inc. (United States)

6. QuidelOrtho Corporation (United States)

7. DiaSorin S.p.A. (Italy)

8. Sekisui Diagnostics LLC (United States)

9. Meridian Bioscience Inc. (United States)

10. bioMérieux SA (France)

Rapid infectious disease detection is shaping the influenza diagnostics market, particularly in response to seasonal outbreak management needs. The influenza diagnostics market is advancing through improved molecular testing and point-of-care technologies. Regulatory frameworks are influencing diagnostic accuracy and deployment standards. Continuous innovation is enhancing speed and reliability of test results.

Industry Development/News

Company Name	Date	Key Development
BD	Aug-23	BD received FDA 510(k) clearance for a respiratory viral panel capable of detecting COVID-19, influenza A and B, and RSV in a single test. The approval strengthens BD’s multiplex diagnostic portfolio and enhances clinical efficiency by enabling consolidated respiratory pathogen detection within laboratory workflows.
Lucira Health	Feb-23	Lucira Health, in collaboration with Pfizer Inc., received FDA emergency use authorization for an over-the-counter home diagnostic test capable of detecting influenza A and B alongside COVID-19. The approval expands at-home respiratory testing capabilities and increases accessibility of multiplex flu diagnostics for consumer healthcare applications.
Hologic Inc.	Oct-22	Hologic Inc. launched its Aptima SARS-CoV-2/Flu multiplex diagnostic test across Europe and North America, enabling simultaneous detection of influenza viruses and COVID-19. The product strengthens molecular diagnostic offerings and supports broader adoption of integrated respiratory testing platforms in clinical laboratories.